Actuate Therapeutics, Inc. Common stock (ACTU) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.98 (-1.41%), Market cap $0.06B, 52-week low–high $1.72 ~ $11.90.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is h
Financial statements, price targets, institutional (13F) holdings and related news for Actuate Therapeutics, Inc. Common stock are updated in real time on BlackAll Trade.
Actuate Therapeutics, Inc. Common stock trades at $0.98 (-1.41%). Real-time quotes and charts are available on BlackAll Trade.
Actuate Therapeutics, Inc. Common stock has a market cap of about $0.06B.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injecti